Table 2.
Top IPA enriched pathways for upregulated genes (p <0.05)
| Enriched pathways | p Value | Molecules | Functions | Disease or function annotation |
|---|---|---|---|---|
| Tox functions | ||||
| Liver enlargement, liver hepatomegaly | 0.0038 | STAT6, ESR2, MIF, GBA | Hepatomegaly | Hepatomegaly |
| Heart failure | 0.0073 | IL16 | Heart failure with preserved left ventricular ejection fraction | Heart failure with preserved left ventricular ejection fraction |
| Nephrosis | 0.0073 | TTC21B | Nephronophthisis type 12 | Nephronophthisis type 12 |
| Liver fibrosis | 0.0100 | IL1A, LEPR, MIF | Activation | Activation of hepatic stellate cells |
| Cardiac necrosis/cell death | 0.0145 | TBX5 | Apoptosis | Apoptosis of endocardial cells |
| Increased levels of CRP | 0.0145 | IL2 | Localization | Increased localization of CRP |
| Liver fibrosis | 0.0145 | IL2 | Hepatic fibrosis | Mild hepatic fibrosis |
| Liver fibrosis | 0.0145 | IL2 | Hepatic fibrosis | Moderate hepatic fibrosis |
| Congenital heart anomaly | 0.0201 | PSEN2, TBX5 | Failure of heart looping | Failure of heart looping |
| Liver damage | 0.0213 | STAT6, MIF | Damage | Damage of liver cells |
| Liver proliferation | 0.0217 | SKP2 | Growth | Arrest in growth of hepatocytes |
| Renal inflammation, Renal nephritis | 0.0217 | IL16 | IgA nephropathy | Primary IgA nephropathy |
| Kidney failure | 0.0217 | GBA | Progressive myoclonic epilepsy type 4 with renal failure | Progressive myoclonic epilepsy type 4 with renal failure |
| Renal damage | 0.0328 | IL2, ITGB6, LEPR, MIF | Damage | Damage of kidney |
| Cardiac necrosis/cell death | 0.0359 | PIN1 | Cell death | Cell death of cardiac stem cells |
| Cardiac inflammation | 0.0392 | IL2, STAT6 | Inflammation | Inflammation of heart |
| Renal atrophy | 0.0460 | AGA, OVOL1 | Atrophy of kidney | Atrophy of kidney |
| Renal proliferation | 0.0499 | SKP2 | Proliferation | Proliferation of renal tubular epithelial cells |
| Tox lists | ||||
| Hepatic fibrosis | 0.0060 | IL2, IL1A, CD40, SDC1 | ||
| Increases renal damage | 0.0214 | IL2, ITGB6, MIF | ||
| Aryl hydrocarbon receptor signaling | 0.0302 | GSTO2, DHFR, IL1A, ESR2 | ||
| Increases liver damage | 0.0437 | IL2, CD40, MIF | ||
| Canonical pathways | ||||
| Crosstalk between dendritic cells and natural killer cells | 0.0043 | IL2, ICAM3, CD40, TREM2 | ||
| dTMP de novo biosynthesis | 0.0046 | DHFR, DHFRL1 | ||
| Amyloid processing | 0.0065 | PSEN2, APH1A, CAPN2 | ||
| Granzyme A signaling | 0.0091 | HIST1H1E, H1FX | ||
| Dendritic cell maturation | 0.0095 | IL1A, COL5A3, LEPR, CD40, TREM2 | ||
| Chondroitin Sulfate degradation (metazoa) | 0.0110 | GM2A, MGEA5 | ||
| Dermatan sulfate degradation (metazoa) | 0.0110 | GM2A, MGEA5 | ||
| Regulation of the epithelial–mesenchymal transition pathway | 0.0112 | WNT8A, PSEN2, CLDN3, APH1A, TWIST1 | ||
| Estrogen-mediated S-phase entry | 0.0132 | SKP2, ESR2 | ||
| Antiproliferative role of TOB in T cell signaling | 0.0151 | IL2, SKP2 | ||
| T helper cell differentiation | 0.0158 | IL2, STAT6, CD40 | ||
| CDP-diacylglycerol biosynthesis I | 0.0166 | AGPAT3, AGPAT1 | ||
| Aryl hydrocarbon receptor signaling | 0.0224 | GSTO2, DHFR, IL1A, ESR2 | ||
| Phosphatidylglycerol biosynthesis II (non-plastidic) | 0.0240 | AGPAT3, AGPAT1 | ||
| Altered T cell and B cell signaling in rheumatoid arthritis | 0.0263 | IL2, IL1A, CD40 | ||
| Communication between innate and adaptive immune cells | 0.0282 | IL2, IL1A, CD40 | ||
| Notch signaling | 0.0309 | PSEN2, APH1A | ||
| Inhibition of matrix metalloproteases | 0.0347 | MMP26, SDC1 | ||
| Granulocyte adhesion and diapedesis | 0.0417 | CLDN3, IL1A, MMP26, SDC1 | ||
| Hematopoiesis from pluripotent stem cells | 0.0457 | IL2, IL1A | ||
| Triacylglycerol biosynthesis | 0.0457 | AGPAT3, AGPAT1 | ||
| Hepatic fibrosis/hepatic stellate cell activation | 0.0479 | IL1A, COL5A3, LEPR, CD40 | ||